Chapters

Transcript

Video

What current ongoing studies are evaluating the role of duvelisib as part of a first-line combinatorial regimen that would be used along with CHOP upon confirmation of PTCL-TFH?


Created by

CMEducation Resources iQ&A PTCL Hematology-Oncology Intelligence Zone

Presenter

Christina Poh, MD

Christina Poh, MD

Physician, Fred Hutchinson Cancer CenterAssistant Professor, Division of Hematology and OncologyUniversity of Washington School of MedicineSeattle, Washington